IBSCIM

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory

Abbreviated Prescribing information for Ibscim (Cimetropium Bromide Tablet) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Cimetropium bromide, a quaternary ammonium semisynthetic derivative of the belladonna alkaloid scopolamine is an antispasmodic drug.

INDICATION: Cimetropium bromide is indicated for the treatment of irritable bowel syndrome.

DOSAGE AND ADMINISTRATION: Adults: Oral dose is 50 milligrams two to three times daily.

CONTRAINDICATION: It is contraindicated in patients having prostatic enlargement, paralytic ileus or pyloric stenosis and also in patients with known hypersensitivity of cimetropium or any of the ingredients of the formulation.

WARNINGS & PRECAUTIONS: Caution when used in patients with diarrhoea or fever, thyrotoxicosis, heart failure and in cardiac surgery. It is not advisable to use in the patients of glaucoma, prostatic hyperplasia, urinary retention, reflux esophagitis, intestinal obstruction, chronic airway obstruction, congestive heart failure and cardiac arrhythmias.

DRUG INTERACTION: Drugs having antimuscarinic properties enhances the effects of Cimetropium. Cimetropium may antagonize the effects of cisapride, domperidone and metoclopramide.

ADVERSE REACTIONS: Mouth dryness, reduced bronchial secretions, pupil dilatation with loss of accommodation and photophobia, skin flushing and dryness, mild transient hypertension, transient bradycardia followed by tachycardia, with palpitations and arrhythmias, blurred vision and micturition difficulty, as well as reduction in tone and motility of the GI tract resulting in constipation. Central nervous system effects are absent or mild, sleepiness and dizziness.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD. Torrent House, Off Ashram Road, Ahmedabad-380 009, INDIA

IN/IBSCIM/FEB 2015/01/AbPI

(Additional information is available on request)